Agilent Technologies (NYSE:A – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 6.180-6.210 for the period, compared to the consensus estimate of 6.060. The company issued revenue guidance of $7.5 billion-$7.5 billion, compared to the consensus revenue estimate of $7.4 billion. Agilent Technologies also updated its Q4 2026 guidance to 1.710-1.740 EPS.
Analysts Set New Price Targets
A has been the subject of a number of recent analyst reports. Piper Sandler initiated coverage on Agilent Technologies in a research report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 price objective for the company. HSBC lowered their target price on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 2nd. TD Cowen lifted their target price on Agilent Technologies from $147.00 to $155.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Finally, Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.24.
Get Our Latest Stock Analysis on A
Agilent Technologies Stock Up 0.3%
Agilent Technologies (NYSE:A – Get Free Report) last issued its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The business had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts anticipate that Agilent Technologies will post 6.05 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. State of Wyoming purchased a new position in shares of Agilent Technologies during the second quarter valued at approximately $35,000. Transamerica Financial Advisors LLC increased its stake in Agilent Technologies by 180.8% during the fourth quarter. Transamerica Financial Advisors LLC now owns 337 shares of the medical research company’s stock worth $46,000 after acquiring an additional 217 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in Agilent Technologies during the 3rd quarter worth approximately $49,000. DV Equities LLC purchased a new stake in Agilent Technologies during the fourth quarter worth approximately $54,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in Agilent Technologies in the 4th quarter valued at $58,000.
Agilent Technologies Company Profile
Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.
Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.
See Also
- Five stocks we like better than Agilent Technologies
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
